KRAS and lung carcinoma: Clinical evidence corroborates the superiority of immunotherapy in prolonging overall survival (OS) relative to chemotherapy in patients with lung cancer (median OS of 4.6 [95% CI 2.8–6.7] months vs 4.2 months [95% CI 3.4–5.9]; P = .03).[8] Further adding to the complexity of therapeutic outcomes are instances wherein KRAS is co-mutated with other genes, thus expanding the potential for nuanced immunotherapeutic strategies.